67 related articles for article (PubMed ID: 18090297)
1. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity.
Caumo A; Guffanti M; Perseghin G; Galli L; Lazzarin A; Luzi L; Castagna A
AIDS; 2007 Nov; 21(17):2366-7. PubMed ID: 18090297
[No Abstract] [Full Text] [Related]
2. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically.
Noor MA; Flint OP; Maa JF; Parker RA
AIDS; 2006 Sep; 20(14):1813-21. PubMed ID: 16954722
[TBL] [Abstract][Full Text] [Related]
3. Effects of ritonavir-boosted darunavir, atazanavir and lopinavir on adipose functions and insulin sensitivity in murine and human adipocytes.
Capel E; Auclair M; Caron-Debarle M; Capeau J
Antivir Ther; 2012; 17(3):549-56. PubMed ID: 22293506
[TBL] [Abstract][Full Text] [Related]
4. No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial.
Dubé MP; Shen C; Greenwald M; Mather KJ
Clin Infect Dis; 2008 Aug; 47(4):567-74. PubMed ID: 18636958
[TBL] [Abstract][Full Text] [Related]
5. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin.
Busti AJ; Bain AM; Hall RG; Bedimo RG; Leff RD; Meek C; Mehvar R
J Cardiovasc Pharmacol; 2008 Jun; 51(6):605-10. PubMed ID: 18520949
[TBL] [Abstract][Full Text] [Related]
6. Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir.
Klein CE; Chiu YL; Cai Y; Beck K; King KR; Causemaker SJ; Doan T; Esslinger HU; Podsadecki TJ; Hanna GJ
J Clin Pharmacol; 2008 May; 48(5):553-62. PubMed ID: 18440920
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment with lopinavir-ritonavir induces a reduction in peripheral adipose depots in mice.
Prot M; Heripret L; Cardot-Leccia N; Perrin C; Aouadi M; Lavrut T; Garraffo R; Dellamonica P; Durant J; Le Marchand-Brustel Y; Binétruy B
Antimicrob Agents Chemother; 2006 Dec; 50(12):3998-4004. PubMed ID: 17000748
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.
Boffito M; Else L; Back D; Taylor J; Khoo S; Sousa M; Pozniak A; Gazzard B; Moyle G
Antivir Ther; 2008; 13(7):901-7. PubMed ID: 19043924
[TBL] [Abstract][Full Text] [Related]
9. GS-8374, a novel HIV protease inhibitor, does not alter glucose homeostasis in cultured adipocytes or in a healthy-rodent model system.
Hruz PW; Yan Q; Tsai L; Koster J; Xu L; Cihlar T; Callebaut C
Antimicrob Agents Chemother; 2011 Apr; 55(4):1377-82. PubMed ID: 21245443
[TBL] [Abstract][Full Text] [Related]
10. Nifedipine-lopinavir/ritonavir severe interaction: a case report.
Baeza MT; Merino E; Boix V; Climent E
AIDS; 2007 Jan; 21(1):119-20. PubMed ID: 17148983
[No Abstract] [Full Text] [Related]
11. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
Di Giambenedetto S; De Luca A; Villani P; Bacarelli A; Ragazzoni E; Regazzi M; Cauda R; Navarra P
HIV Med; 2008 Apr; 9(4):239-45. PubMed ID: 18366448
[TBL] [Abstract][Full Text] [Related]
12. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults.
Noor MA; Parker RA; O'Mara E; Grasela DM; Currie A; Hodder SL; Fiedorek FT; Haas DW
AIDS; 2004 Nov; 18(16):2137-44. PubMed ID: 15577646
[TBL] [Abstract][Full Text] [Related]
13. Effect of atazanavir and ritonavir on the differentiation and adipokine secretion of human subcutaneous and omental preadipocytes.
Jones SP; Waitt C; Sutton R; Back DJ; Pirmohamed M
AIDS; 2008 Jul; 22(11):1293-8. PubMed ID: 18580608
[TBL] [Abstract][Full Text] [Related]
14. The metabolic effects of lopinavir/ritonavir in HIV-negative men.
Lee GA; Seneviratne T; Noor MA; Lo JC; Schwarz JM; Aweeka FT; Mulligan K; Schambelan M; Grunfeld C
AIDS; 2004 Mar; 18(4):641-9. PubMed ID: 15090769
[TBL] [Abstract][Full Text] [Related]
15. Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V.
Nijhuis M; Wensing AM; Bierman WF; de Jong D; Kagan R; Fun A; Jaspers CA; Schurink KA; van Agtmael MA; Boucher CA
J Infect Dis; 2009 Sep; 200(5):698-709. PubMed ID: 19627247
[TBL] [Abstract][Full Text] [Related]
16. The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.
Chetchotisakd P
Expert Rev Anti Infect Ther; 2009 Sep; 7(7):801-5. PubMed ID: 19735222
[TBL] [Abstract][Full Text] [Related]
17. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
Delfraissy JF; Flandre P; Delaugerre C; Ghosn J; Horban A; Girard PM; Norton M; Rouzioux C; Taburet AM; Cohen-Codar I; Van PN; Chauvin JP
AIDS; 2008 Jan; 22(3):385-93. PubMed ID: 18195565
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection.
Khachi H; O'Connell R; Ladenheim D; Orkin C
J Antimicrob Chemother; 2009 Oct; 64(4):871-3. PubMed ID: 19628472
[No Abstract] [Full Text] [Related]
19. Single-dose lopinavir-ritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers.
Lee GA; Lo JC; Aweeka F; Schwarz JM; Mulligan K; Schambelan M; Grunfeld C
Clin Infect Dis; 2006 Sep; 43(5):658-60. PubMed ID: 16886163
[TBL] [Abstract][Full Text] [Related]
20. Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers.
Lee GA; Rao M; Mulligan K; Lo JC; Aweeka F; Schwarz JM; Schambelan M; Grunfeld C
AIDS; 2007 Oct; 21(16):2183-90. PubMed ID: 18090045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
